Craig-Hallum analyst Alex Novak lowered the firm’s price target on Accelerate Diagnostics (AXDX) to $2 from $5 and keeps a Hold rating on the shares. The firm notes Q4 was another challenged quarter for the company. Accelerate has still not seen any of the Becton Dickinson (BDX) partnership progress convert into meaningful revenue, Craig-Hallum adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXDX:
- Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
- Accelerate Diagnostics files to sell units, no amount given
- Accelerate Diagnostics announces collaboration with Bruker
- Accelerate Diagnostics Reports Third Quarter 2023 Results
Questions or Comments about the article? Write to editor@tipranks.com